Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001;2000(2):CD002993.
doi: 10.1002/14651858.CD002993.

Cyclosporin as an oral corticosteroid sparing agent in stable asthma

D J Evans  1 , P Cullinan, D M Geddes
Affiliations

Cyclosporin as an oral corticosteroid sparing agent in stable asthma

D J Evans et al. Cochrane Database Syst Rev. 2001.

Abstract

Background: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that reduce the need for chronic dosing with oral steroids. Cyclosporin is an immunosuppressive agent and has benefits in the treatment of a number of inflammatory disorders. It has therefore been identified as an potentially useful agent in the treatment of chronic severe asthma both in terms of possible efficacy and as a steroid sparing agent.

Objectives: The objective of this review was to assess the effects of adding cyclosporin to oral steroids in the treatment of chronic steroid dependent asthmatics.

Search strategy: The Cochrane Airways Group trials register and reference lists of identified articles were searched.

Selection criteria: Randomised trials looking at the addition of cyclosporin compared to placebo in adult steroid dependent asthmatics.

Data collection and analysis: Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information.

Main results: Three trials fulfilled the criteria for inclusion in the review and a total of 106 patients were recruited into these studies. Data from 98 patients could be analysed. There was a small but significant treatment effect for cyclosporin in terms of steroid dose reduction (SMD -0.5, 95% CI -1.0, -0.04). No meta-analyses could be performed for measures of lung function although one study showed small, but significant improvements in lung spirometry.

Reviewer's conclusions: The changes with cyclosporin are small and of questionable clinical significance. Given the side effects of cyclosporin, the evidence available does not recommend routine use of this drug in the treatment of oral corticosteroid dependent asthma.

PubMed Disclaimer

Conflict of interest statement

Prof E. Haydn Walters has acted as a consultant to Norvartis who manufacture Neoral a form of cyclosporin.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Alexander 1992 {published data only}
    1. Alexander A, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid‐dependent chronic severe asthma. Lancet 1992;339:324‐8. - PubMed
Lock 1996 {published data only}
    1. Lock SH, Kay AB, Barnes NC. Double‐blind, placebo‐controlled study of Cyclosporin A as a corticosteroid‐sparing agent in corticosteroid‐dependent asthma. American Journal of Respiratory and Critical Care Medicine 1996;153:509‐14. - PubMed
Nizankowska 1995 {published data only}
    1. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroid‐dependent bronchial asthma with cyclosporin. European Respiratory Journal 1995;8:1091‐9. - PubMed

References to studies excluded from this review

Kay 2003 {published data only}
    1. Kay B. A pilot study to assess the efficacy of novel cyclosporin analogues in steroid resistant asthma. National Research Register (UK) 2003.
Khan 2000 {published data only}
    1. Khan LN, Kon OM, MacFarlane AJ, Meng Q, Ying S, Barnes NC, et al. Attenuation of the allergen‐induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin‐5, granulocyte macrophage colony‐stimulating factor, and eotaxin. American Journal of Respiratory & Critical Care Medicine 2000;162(4):1377‐82. - PubMed
    1. Ying S, Khan LN, Meng Q, Barnes NC, Kay A B. Cyclosporin A, apoptosis of BAL T‐cells and expression of Bcl‐2 in asthmatics. European Respiratory Journal 2003;22(2):207‐12. - PubMed
Matusiewicz 1992 {published data only}
    1. Matusiewicz R, Urbankowska B. Effect of cyclosporine A on clinical state and spirometric parameters in patients with steroid‐dependent bronchial asthma. Pneumonologie I Alergologia Polska 1992;60:53‐7. - PubMed
Matusiewicz 1997 {published data only}
    1. Matusiewicz R, Rotkiewicz‐Piorun A. Treatment of severe forms of corticosteroid‐dependent chronic asthma with immunosuppressive and anti‐homotoxic agents [Behandlung schwerer Formen von kortikoidabhangigem Bronchialasthma mit Immunsuppressiva und Antihomotoxischen Mitteln]. Biologische Medizin 1997;26(2):67‐72.
Mungan 1995 {published data only}
    1. Mungan D, Misirligil Z, Sin B, Kaya A, Demirel Y, Gurbuz L. Cyclosporin in steroid dependent asthma. Allergology et Immunopathology 1995;23(5):202‐6. - PubMed
Szceklik 1991 {published data only}
    1. Szczeklik A, Nizankowska E, Dworski R, Domagala B, Pinis G. Cyclosporin for steroid‐dependent asthma. Allergy 1991;46:312‐5. - PubMed

Additional references

Anonymous 1992
    1. Anonymous. Cyclosporin in chronic severe asthma. Lancet 1992;339:338‐9. - PubMed
Arima 1994
    1. Arima M, Yukawa T, Terashi Y, Makino S. Effect of inhaled cyclosporin A on the allergen induced late phase asthmatic response and increased airway hyperresponsiveness in a guinea pig model of asthma. Japanese Journal of Allergology 1994;43(11):1316‐25. - PubMed
Calderon1992
    1. Calderon E, Lockey RF, Bukantz SC, Coffey RG, Ledford DK. Is there a role for cyclosporin in asthma. Journal of Allergy and Clinical Immunology 1992;89(2):629‐35. - PubMed
Morley 1992
    1. Morley J. Cyclosporin A in asthma therapy; a pharmacological rationale. Journal of Autoimmunity 1992;5(Suppl A):265‐9. - PubMed
Schmidt 1993
    1. Schmidt J, Fleibner S, Heimann‐Weitschat I, Lindstaedt R, Pomberg B, Werner U, et al. Effect of corticosteroids, cyclosporin A, and methotrexate on cytokine release from moncytes and T cell subsets. Immunopharmacology 1994;27:173‐9. - PubMed

Publication types

MeSH terms